A new advance in the treatment of diabetes has been published, Lilly has presented the results of several studies on a new basal insulin of weekly administration called Effsitora Alfa.These studies have shown that EFSITORA ALFA can reduce HBA1C levels comparable to daily insulin in people with type 1 and type 2 diabetes.
In the QWINT-5 trial, the efficacy and safety of EFSITORA ALFA was evaluated compared to the swallowing insulin, which is administered once a day.The results showed that EFSITORA ALFA achieved an HBA1C reduction of 0.53%, very similar to 0.59% achieved by the swallowing insulin.This means that the final levels of HBA1C were 7.37% with EFSITOR and 7.32% with swallowing insulin.
One of the greatest advantages of Effsitora Alfa is that it only requires a weekly injection, which could mean more than 300 punctures less a year for people with diabetes.
In addition, the studies showed that the percentage of time in range (glucose between 70-180 mg/dl) was similar for both insulins, and clinically significant hypoglycemic events rates were also comparable.
In addition to the QWINT-5 trial, other studies were conducted with EFSITORA ALFA in people with type 2 diabetes. In these studies, EFSITORA ALFA also proved to be as effective as daily insulins in the reduction of HBA1C, with promising results in terms of control of control ofglucose and reduction of hypoglycemic events.
These new data could mean an important change in the way diabetes is handled.
The possibility of a weekly basal insulin that offers a control similar to that of daily insulins is great news for many people with diabetes.We will remain attentive to more studies and evaluations to see how this new option can be integrated into daily treatment.
What do you think of the idea of a weekly basal insulin?
Do you think you can keep glucose still doing sports or other activities?
@fer - Diabetes Tipo 1 desde 1.998 | FreeStyle Libre 3 | Ypsomed mylife YpsoPump + CamAPS FX | Sin complicaciones. Miembro del equipo de moderación del foro. Co-Autor de Vivir con Diabetes: El poder de la comunidad online, parte de los ingresos se destinan a financiar el foro de diabetes y mantener la comunidad online activa.
@fer - Diabetes Tipo 1 desde 1.998 | FreeStyle Libre 3 | Ypsomed mylife YpsoPump + CamAPS FX | Sin complicaciones. Miembro del equipo de moderación del foro. Co-Autor de Vivir con Diabetes: El poder de la comunidad online, parte de los ingresos se destinan a financiar el foro de diabetes y mantener la comunidad online activa.
Insulins will be better.There is a lot of competition between pharmaceuticals. I hope they advance with intelligent insulin.That would be the most.
Hija de 35 años , diabética desde los 5. Glico: normalmente de 6 , pero 6,7 la última ( 6,2 marcaba el Free) Fiasp: 4- 4- 3 Toujeo: 20
regina said: insulins will be better.There is a lot of competition between pharmaceuticals. I hope they advance with intelligent insulin.That would be the most.
No signature configured, update it from user's profile.
It would be great, but I understand that it is more for basal than for fast. In another case, a very strict diet of hydrates should be made, eat at the same time and not hormal.
DM 2 con páncreas agotado desde diciembre 2020. 51 años entonces. HG diciembre 2020: 15.9. Última HG: julio 2024 5.8 Abasaglar 9 unidades. Metformina, 1000/0/1000. Humalog junior: 2 unid en desayuno y luego en función de lo que coma.
Smart insulins are something else.Here they explain Link In principle it is an insulin complex and a molecule that masks and is sensitive to glucose.In the presence of glucose the insulin is undone and released.